Cristian Oswaldo Hernández-Ramírez

Dr. Cristian Oswaldo Hernández-Ramírez

University of Guadalajara, Guadalajara, Jalisco, Mexico
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
José Francisco Muñoz-ValleJosé Francisco Muñoz-Valle
José Francisco Muñoz-Valle
GSGabriela Athziri Sánchez-Zuno
Gabriela Athziri Sánchez-Zuno
MFMónica Matuz Flores
Mónica Matuz Flores
Cristian Oswaldo Hernández-RamírezCristian Oswaldo Hernández-Ramírez
Cristian Oswaldo Hernández-Ramírez
SPSaúl Alberto Díaz Pérez
Saúl Alberto Díaz Pérez
JHJorge Hernández-Bello
Jorge Hernández-Bello
Several studies have reported the benefits and safety of heterologous vaccination among different approved vaccines; however, there are no specific reports on the effects of vaccination with the Ad5-nCoV and other vaccines of the same or different technologies. In the present study, we evaluated the neutralizing antibodies percentage against SARS-CoV-2 in Mexican patients immunized with the Ad5-nCoV vaccine six months after its application. Moreover, the effect of the heterologous vaccination with the Ad5-nCoV vaccine and a booster dose of ChAdOx1-S-Nov-19, Ad26.COV2.S, BNT162b2, or mRNA-127 were determined. Our results suggest that a heterologous regimen of one dose with Ad5-nCoV vaccine followed by a booster dose of a different vaccine is safe and induces a stronger humoral immune response.

4 March 2026 in Vaccines
Verified
Journal Article
Open access
PDF file
José Francisco Muñoz-ValleJosé Francisco Muñoz-Valle
José Francisco Muñoz-Valle
GMGabriela Macedo
Gabriela Macedo
FTFrancisco Javier Turrubiates-Hernández
Francisco Javier Turrubiates-Hernández
JHJorge Hernández-Bello
Jorge Hernández-Bello
SGSamuel García-Arellano
Samuel García-Arellano
OVOliver Viera-Segura
Oliver Viera-Segura
Background: Measles remains a global public health threat despite the availability of an effective vaccine and substantial progress toward elimination in many countries. Outbreaks in highly vaccinated settings suggest that waning vaccine-induced immunity, particularly among adults, may create silent susceptibility gaps capable of sustaining viral transmission. Aim: To evaluate age- and cohort-specific patterns of measles-specific antibody levels in Mexican adults and to examine evidence suggesting lower vaccine-induced antibody levels in younger vaccinated cohorts. Methods: A cross-sectional seroepidemiological study was conducted among 302 voluntary blood donors aged 18–70 years. Demographic, clinical, and vaccination data were collected through structured interviews. Serum anti-measles-virus (MV) IgG levels were quantified using a commercial ELISA. Antibody concentrations were analyzed according to age, sex, vaccination history, self-reported measles infection, and historical vaccination strategies. Multivariate linear models were applied to identify factors associated with IgG levels. Results: Anti-MV IgG seropositivity (>200 mIU/mL) was 67.2%, with a geometric mean concentration (GMC) of 270.43 mIU/mL. A positive correlation was observed between age and antibody levels (rs = 0.161, p = 0.005). Individuals born before the introduction of the measles vaccine (pre-1970) had significantly higher GMCs (1096.63 mIU/mL) than younger cohorts. A history of natural infection tended to be associated with higher antibody levels (GMC: 428.38 vs. 257.24 mIU/mL; p = 0.051). In multivariate analysis, historical vaccination strategy emerged as the primary factor associated with antibody levels, whereas age alone was not significant. Conclusions: Cohort-specific differences in measles IgG levels suggest generational patterns of immunity and are consistent with diminished vaccine-induced antibody levels in younger adults in the absence of natural boosting. These findings highlight the importance of ongoing serological surveillance in post-elimination settings and underscore the need for targeted public health interventions.

18 May 2026 in Sustainability
Verified
Journal Article
Open access
PDF file
FTFrancisco Javier Turrubiates-Hernández
Francisco Javier Turrubiates-Hernández
José Francisco Muñoz-ValleJosé Francisco Muñoz-Valle
José Francisco Muñoz-Valle
GGGuillermo González-Estevez
Guillermo González-Estevez
JHJorge Hernández-Bello
Jorge Hernández-Bello
Alexis Missael Vizcaíno-QuirarteAlexis Missael Vizcaíno-Quirarte
Alexis Missael Vizcaíno-Quirarte
NRNorma A. Ruvalcaba Romero
Norma A. Ruvalcaba Romero
Social entrepreneurship has emerged as a strategic approach to addressing collective needs through innovative and sustainable solutions. While many instruments have traditionally focused on business and organizational metrics, a significant gap remains in tools specifically validated for the professional and cultural context of health sciences in Latin America. Grounded in a multidimensional theoretical framework of social entrepreneurship traits, this study aimed to validate a questionnaire designed to measure social entrepreneurship among 1129 Mexican health science students. Following exploratory factor analysis using principal axis factoring and confirmatory factor analysis, a refined 17-item three-dimensional structure was identified, comprising innovative, execution, and social traits. The model demonstrated moderate fit (χ2 = 580.468, p <0.001; CFI = 0.831; RMSEA = 0.084) and preliminary internal consistency. Measurement invariance across sex and semester was also supported. These findings provide a context-specific tool for exploring initial entrepreneurial potential, enabling higher education institutions to design targeted programs that foster proactive innovation and social commitment toward sustainable development.

13 March 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Cristian Oswaldo Hernández-RamírezCristian Oswaldo Hernández-Ramírez
Cristian Oswaldo Hernández-Ramírez
HCHazael Ramiro Ceja-Gálvez
Hazael Ramiro Ceja-Gálvez
KAKevin Javier Arellano Arteaga
Kevin Javier Arellano Arteaga
EMElvira Miramontes-Luna
Elvira Miramontes-Luna
JHJorge Hernández-Bello
Jorge Hernández-Bello
José Francisco Muñoz-ValleJosé Francisco Muñoz-Valle
José Francisco Muñoz-Valle
Background/Objectives: COVID-19 is an infectious disease caused by SARS-CoV-2. The innate immune response constitutes the first line of antiviral defense. Notably, interferon-stimulated genes, such as those belonging to the oligoadenylate synthetase (OAS) family, have been implicated in host susceptibility and the response to SARS-CoV-2 infection. However, the extent to which OAS gene expression varies across SARS-CoV-2 variants remains insufficiently characterized. Its relationship with clinical outcomes in hospitalized patients is also unclear. This study aimed to evaluate OAS gene expression and its association with inflammatory markers and clinical outcomes in patients with severe COVID-19. Methods: An analytical cross-sectional study was conducted in patients hospitalized with severe COVID-19 between October 2021 and February 2022. SARS-CoV-2 infection and viral variants were prescreened at admission. Clinical parameters were recorded, including serum cytokine levels (IL-1β, IL-6, IL-8, MCP-1, IFN-α, IFN-β, IFN-γ, and TNF-α), and hematological indices (neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio). The COVID-GRAM risk score, treatment, and hospitalization outcomes were recorded. Relative mRNA expression of OAS1, OAS2, OAS3, and OAS-L was quantified by quantitative PCR, using TaqMan probes. Results: A total of 76 hospitalized patients with severe COVID-19 were included. In-hospital mortality was 32.9%, with a predominance of male patients (60%). Nearly 50% of non-survivors were infected with the Omicron variant. OAS1, OAS2, and OAS3 were overexpressed in hospitalized patients with severe COVID-19 compared with healthy subjects (HS) (log2 fold change [95% CI]: OAS2: 4.312 [4.161–4.602], OAS3: 1.660 [1.485–1.916]; p = 0.0040 for both). Expression of OAS2 and OAS3 was significantly increased in survivors compared with HS (log2 fold change: 4.312 [4.161–4.602] and 1.711 [1.485–1.990], respectively; p = 0.0009 and p = 0.0025). Similar increases were observed in non-survivors (4.554 [4.251–4.743] and 1.640 [1.081–2.301], respectively; p = 0.0002 and p = 0.0061) compared with HS. Conclusions: OAS genes, particularly OAS2 and OAS3, are overexpressed in severe COVID-19. This upregulation was comparable between Delta and Omicron infections, suggesting that the activation of this antiviral pathway is driven more by disease severity than by the specific viral variant.